PRA Health Sciences, Inc. (NASDAQ:PRAH) – First Analysis issued their Q2 2018 EPS estimates for shares of PRA Health Sciences in a research note issued on Wednesday. First Analysis analyst S. Schwartz expects that the medical research company will earn $0.92 per share for the quarter.

A number of other research analysts have also commented on PRAH. SunTrust Banks, Inc. restated a “buy” rating on shares of PRA Health Sciences in a research note on Wednesday, August 9th. Citigroup Inc. restated a “buy” rating and issued a $93.00 price objective (up from $90.00) on shares of PRA Health Sciences in a research note on Thursday, August 10th. Credit Suisse Group lifted their price objective on shares of PRA Health Sciences from $80.00 to $84.00 and gave the company an “outperform” rating in a research note on Tuesday, August 8th. Robert W. Baird lifted their price objective on shares of PRA Health Sciences from $82.00 to $83.00 and gave the company an “outperform” rating in a research note on Tuesday, August 8th. Finally, Jefferies Group LLC restated a “buy” rating and issued a $92.00 price objective (up from $88.00) on shares of PRA Health Sciences in a research note on Thursday, August 10th. Two equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. PRA Health Sciences has a consensus rating of “Buy” and an average target price of $81.22.

TRADEMARK VIOLATION NOTICE: “First Analysis Weighs in on PRA Health Sciences, Inc.’s Q2 2018 Earnings (PRAH)” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/08/17/first-analysis-weighs-in-on-pra-health-sciences-inc-s-q2-2018-earnings-prah.html.

PRA Health Sciences (NASDAQ PRAH) traded up 0.72% during midday trading on Thursday, reaching $75.70. 388,570 shares of the company’s stock traded hands. PRA Health Sciences has a 1-year low of $48.42 and a 1-year high of $80.99. The company has a market capitalization of $4.74 billion, a PE ratio of 48.87 and a beta of 0.45. The firm’s 50 day moving average price is $75.23 and its 200-day moving average price is $67.76.

PRA Health Sciences (NASDAQ:PRAH) last posted its quarterly earnings results on Monday, August 7th. The medical research company reported $0.62 EPS for the quarter, missing the consensus estimate of $0.72 by $0.10. PRA Health Sciences had a net margin of 5.15% and a return on equity of 21.17%. The business had revenue of $457.90 million during the quarter, compared to analysts’ expectations of $447.79 million. During the same period in the previous year, the company posted $0.63 earnings per share. PRA Health Sciences’s revenue for the quarter was up .5% compared to the same quarter last year.

A number of institutional investors have recently made changes to their positions in PRAH. First Bank & Trust boosted its position in shares of PRA Health Sciences by 1.6% in the second quarter. First Bank & Trust now owns 3,211 shares of the medical research company’s stock worth $241,000 after buying an additional 52 shares during the last quarter. Renaissance Group LLC boosted its position in shares of PRA Health Sciences by 2.5% in the second quarter. Renaissance Group LLC now owns 5,239 shares of the medical research company’s stock worth $393,000 after buying an additional 126 shares during the last quarter. State Board of Administration of Florida Retirement System boosted its position in shares of PRA Health Sciences by 0.6% in the first quarter. State Board of Administration of Florida Retirement System now owns 21,892 shares of the medical research company’s stock worth $1,428,000 after buying an additional 140 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of PRA Health Sciences by 12.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,488 shares of the medical research company’s stock worth $112,000 after buying an additional 160 shares during the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. boosted its position in shares of PRA Health Sciences by 1.9% in the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 8,505 shares of the medical research company’s stock worth $638,000 after buying an additional 160 shares during the last quarter. Institutional investors own 96.76% of the company’s stock.

In related news, major shareholder Pra Investors L.P. Kkr sold 9,500,000 shares of the business’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $74.85, for a total transaction of $711,075,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Colin Shannon sold 400,000 shares of the business’s stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $74.85, for a total transaction of $29,940,000.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 10,000,000 shares of company stock worth $748,500,000. 2.10% of the stock is owned by insiders.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Earnings History and Estimates for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.